Biocartis Group NV
BCART
Company Profile
Business description
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an MDx Idylla molecular diagnostic system for oncology and infectious disease segments. Its products include EGFR mutation assay, BRAF mutation test, NRAS mutation test, respiratory panel, etc. The firm derives the majority of its revenues from product sales.
Contact
Generaal de Wittelaan 11 B
Mechelen2800
BELT: +32 15632600
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
420
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.70 | 43.70 | 0.52% |
| CAC 40 | 7,873.83 | 23.73 | 0.30% |
| DAX 40 | 23,638.56 | 72.02 | 0.31% |
| Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
| FTSE 100 | 8,602.92 | 2.06 | -0.02% |
| HKSE | 23,108.27 | 441.19 | -1.87% |
| NASDAQ | 19,010.09 | 301.74 | 1.61% |
| Nikkei 225 | 38,183.26 | 539.00 | 1.43% |
| NZX 50 Index | 12,786.74 | 109.99 | 0.87% |
| S&P 500 | 5,886.55 | 42.36 | 0.72% |
| S&P/ASX 200 | 8,269.00 | 35.50 | 0.43% |
| SSE Composite Index | 3,374.87 | 5.63 | 0.17% |